Certara (NASDAQ:CERT) Shares Gap Down – Here’s What Happened

Shares of Certara, Inc. (NASDAQ:CERT) gapped down before the market opened on Thursday . The stock had previously closed at $6.03, but opened at $5.73. Certara shares last traded at $5.7540, with a volume of 535,302 shares trading hands.

Analysts Set New Price Targets

A number of brokerages have issued reports on CERT. Craig Hallum reduced their price target on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a report on Tuesday, May 12th. BMO Capital Markets reduced their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. Robert W. Baird reduced their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, May 12th. Barclays reduced their price target on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Finally, Stephens reduced their price target on shares of Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.85.

Certara Stock Down 5.6%

The firm has a market capitalization of $885.97 million, a PE ratio of -56.95 and a beta of 1.49. The business’s 50 day simple moving average is $5.60 and its 200 day simple moving average is $7.10. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. Certara’s revenue for the quarter was up .8% on a year-over-year basis. During the same period in the previous year, the business earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities research analysts forecast that Certara, Inc. will post 0.24 earnings per share for the current year.

Hedge Funds Weigh In On Certara

Several large investors have recently modified their holdings of CERT. Northwestern Mutual Wealth Management Co. grew its holdings in Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after purchasing an additional 2,870 shares during the last quarter. Osaic Holdings Inc. grew its holdings in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after purchasing an additional 4,930 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in Certara during the 1st quarter valued at about $78,000. Finally, Kera Capital Partners Inc. bought a new position in Certara during the 1st quarter valued at about $80,000. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.